XML 26 R15.htm IDEA: XBRL DOCUMENT
v3.25.3

Supplemental Financial Information | 9 Months Ended
--- | ---
Sep. 30, 2025
Other Balance Sheet Details [Abstract] |
Supplemental Financial Information | Supplemental Financial Information Inventory consisted of the following:
(in millions) | September 30, 2025 |  | December 31, 2024
Raw materials | $ | 40.1 |  |  | $ | 33.7 |
Work in process | 13.2 |  |  | 10.9 |
Finished goods | 16.2 |  |  | 12.8 |
| 69.5 |  |  | 57.4 |
Less inventory reserves | (0.2) |  |  | — |
Total inventory | $ | 69.3 |  |  | $ | 57.4 |
Prior to FDA approval of CRENESSITY in December 2024, all costs related to its manufacturing were expensed as R&D in the period incurred. As a result, our physical inventories as of September 30, 2025 and December 31, 2024 included active pharmaceutical product with no cost basis. Costs related to the manufacturing of bulk drug product, finished bottling, and other labeling activities that occurred post-FDA approval are included in the inventory values as of September 30, 2025 and December 31, 2024. Accounts payable and accrued liabilities consisted of the following:
(in millions) | September 30, 2025 |  | December 31, 2024
Sales rebates and reserves | $ | 237.9 |  |  | $ | 144.2 |
Accrued employee related costs | 105.1 |  |  | 107.5 |
Accrued development costs | 82.4 |  |  | 50.8 |
Current branded prescription drug fee | 39.0 |  |  | 49.2 |
Accounts payable and other accrued liabilities | 119.9 |  |  | 109.9 |
Total accounts payable and accrued liabilities | $ | 584.3 |  |  | $ | 461.6 |
Other noncurrent liabilities consisted of the following:
(in millions) | September 30, 2025 |  | December 31, 2024
Noncurrent income taxes payable | $ | 195.5 |  |  | $ | 160.7 |
Other noncurrent liabilities | 0.2 |  |  | 5.5 |
Total other noncurrent liabilities | $ | 195.7 |  |  | $ | 166.2 |
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.
(in millions) | September 30, 2025 |  | September 30, 2024
Cash and cash equivalents | $ | 340.2 |  |  | $ | 349.1 |
Restricted cash included in other noncurrent assets | 8.0 |  |  | 8.0 |
Total cash, cash equivalents, and restricted cash | $ | 348.2 |  |  | $ | 357.1 |

X
- Definition Other balance sheet details. + References No definition available. + Details
Name: | nbix_OtherBalanceSheetDetailsAbstract
Namespace Prefix: | nbix_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration